The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Updated data with INCA033989, a mutant CALR-specific mAb, in patients with MPNs
Claire Harrison, MD, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, presents updates from Phase I trials (NCT05936359, NCT06034002) investigating the mutant calreticulin-specific monoclonal antibody (mAb) INCA033989 in patients with myelofibrosis (MF). Prof. Harrison provides insight into the encouraging safety and efficacy of this agent and highlights its potential as a disease-modifying treatment for myeloproliferative neoplasms (MPNs). This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
